Navigation Links
Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium
Date:11/9/2007

Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com. The information in our website is not incorporated by reference into this press release and is included as an inactive textual reference only.

KERYX CONTACT:

Lauren Fischer

Director - Investor Relations

Keryx Biopharmaceuticals, Inc.

Tel: 212.531.5965

E-mail: lfischer@keryx.com


'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2008)...RNewswire-FirstCall/ -- Eli Lilly and Company,(NY...g Application (sNDA) from,the U.S. Food and Drug ...Cl),for the management of chronic pain. Lilly pla...of 2009, adding data from a recently completed pos... knee. , The decision does not affect dulox...
(Date:11/25/2008)...prove recovery , , Audio and Web Video Reso... Mayo Clinic News Blog. Please see the bottom of t..., Minn., Nov. 25 A Mayo...don,t think they,re having a stroke -- and as a re...ion worsens. The findings appear in the current is...
(Date:11/25/2008)...25 Pharmacyclics, Inc.,... has completed a Phase 1,clinical trial with PCI-...molecule Factor VIIa inhibitor. The trial was cond...ate the safety and pharmacologic effect of,PCI-27... in a linear dose,response in the International N...
(Date:11/24/2008)...4 Leaders of Schering-Pl...update for investors on the company,s research pip...o that includes 46 new entities in clinical trials...studies. , , "Research and development is a...e continue our transformation," said Fred Hassan, ...
Breaking Medicine Technology:Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 4Do You Know You're Having a Stroke? 2Do You Know You're Having a Stroke? 3Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 2Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 3Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 4Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 2Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 3Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 4Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 5LI COR Introduces the Odyssey 28R 29 Two Color NIR Fluorescent Protein Molecular Weight Marker 8270 1LI COR Introduces the Odyssey 28R 29 Two Color NIR Fluorescent Protein Molecular Weight Marker 8270 2Cephalon Launches National Consumer Awareness Initiative on Appropriate Use of Prescription Opioid Medications 8265 1Cephalon Launches National Consumer Awareness Initiative on Appropriate Use of Prescription Opioid Medications 8265 2Sysmex Announces Clinical Laboratory Software Name Change 8261 1Solos Endoscopy Inc in Final Stages to Upgrade Pink Sheet Status from Limited to Current Information 8256 1Solos Endoscopy Inc in Final Stages to Upgrade Pink Sheet Status from Limited to Current Information 8256 2
... PASADENA, Calif.--(BUSINESS WIRE)--Mar 20, 2007 -...unced today that,majority-owned subsidiary Calando...eedings of the National Academy of Sciences,(PNAS)...ple,systemic dosing with Calando,s lead siRNA the...ary technologies in targeted,polymeric delivery sy...
... Iontophoretic Drug Delivery System, dermal patch ... and epinephrine (IDDS), SEATTLE, March 20, 2007...arma") Seattle, WA, a transdermal drug delivery co...ous Technologies, Inc.,("TTI"), Tokyo, Japan ann...nology, which administers lidocaine and epinephrin...
Other Medicine Technology:Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on,Targeted, Systemic Delivery of siRNA 2Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on,Targeted, Systemic Delivery of siRNA 3Dharma Therapeutics Shows IDDS Is Effective in Reducing Pain,Associated With Insertion of an Intravenous Catheter in Their Phase,2 Clinical Trial 2Dharma Therapeutics Shows IDDS Is Effective in Reducing Pain,Associated With Insertion of an Intravenous Catheter in Their Phase,2 Clinical Trial 3
(Date:12/1/2008)... nicotine use, personality illnesses common, study...ws) -- Psychiatric disorders are common among youn...ent, a new report shows. , To reach this findin...,000 respondents, aged 19 to 25, who took part in ...elated Conditions. , The study found that 45.8 ...
(Date:12/1/2008)...see problems with the agency,s goals, commitment a...hDay News) -- Responding to criticism that it has ...ply, the U.S. Food and Drug Administration release... consumers. , Among the most important changes ...r relationships with state and local health depart...
(Date:12/1/2008)...analysis of the National Cancer Institute,s cancer...der women experience delayed or incomplete radiati...and that this suboptimal care can lead to worse ou...ll Medical College and colleagues found that among...0 breast cancer registry patients aged 65 and olde...
(Date:12/1/2008)...ELLE, N.Y., Dec. 1 Due to the urge...n the field of AIDS/HIV research and clinical care...vide complimentary access to all archival online i...nd of December in honor of World AIDS Day. Free on...nd STDs ( www.liebertpub.com/apc ) and AIDS Re...
Breaking Medicine News(10 mins):Health News:Few Young Adults Seek Treatment for Psych Disorders 2Health News:FDA Touts Efforts to Enhance Food Safety 2Health News:FDA Touts Efforts to Enhance Food Safety 3Health News:FDA Touts Efforts to Enhance Food Safety 4Health News:Delays in radiation therapy lead to increased breast cancer recurrence 2Health News:Mary Ann Liebert, Inc. Provides Free Online Journal Access in Recognition of World AIDS Day 2
...new head of the Ontario Medical Association has ma...t priority. // He has asked the provincial govern...nadian-trained doctors working in the US to come h...nine thousand physicians who were trained in Canad...
...among doctors working in the radiological departme...cher and assistant professor at the Department of ...and Medical Center has come up with a new techniqu...t would not obstruct their movement and would allo...
...lth service is losing more than ?50m because of pe...te years of similar complaint by NHS managers the ...sson from Hinchingbrooke Hospital in Huntingdon sa... do not turn up as they feel better while others f...
...shown that cutting back a few calories from our di...event certain age related changes in cells. // S...te on Aging have found that eating a little less f...a lifespan can reduce or even reverse aging-relate...
Other Medicine News:Health News:Ontario Medical Association Planning To Lure Back Expat Doctors 2Health News:Cut Calories to Age Gracefully 2Health News:Cut Calories to Age Gracefully 3
Integrated electronics, single-chip CCD camera with PAL and NTSC output. PAL output at 460 lines, NTSC output at 470 lines, focal length 30mm. 90mm length x 20mm diameter.
Large image and wide-angle design.
Large-image field with titanium couplers for c-mount scopes. 30mm focal length.
High intensity lamp with built-in, switchable spare lamp. Low-noise fan with reduced air turbulence.
Medicine Products: